M-ESZOPICLONE 1 MG
ESZOPICLONE : 1 MG · DIN 02551187 · MANTRA PHARMA INC
Health Canada status: MARKETED
What is M-ESZOPICLONE?
M-ESZOPICLONE 1 MG contains ESZOPICLONE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02551187, held by MANTRA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Dec-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is M-ESZOPICLONE used for?
Short-term (7-10 days) treatment and symptomatic relief of insomnia (difficulty falling asleep, frequent nocturnal awakenings, or early morning awakenings) with impaired daytime functioning.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02551187 |
|---|---|
| Brand name | M-ESZOPICLONE |
| Generic / active ingredient | ESZOPICLONE : 1 MG |
| Manufacturer | MANTRA PHARMA INC |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05CF04 ESZOPICLONE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Dec-2024 |
How is it administered?
Starting dose 1 mg; max 3 mg (2 mg for elderly/impaired) once daily immediately before bedtime. Do not break or crush. Short-term use (7-10 days) recommended.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: General standard for USP tablets, though specific section 11 was not fully detailed in text, section 13/11 implies standard conditions).
How is it supplied?
1 mg: Bottles of 30, cartons of 100 (blisters), cartons of 3. 2 mg: Bottles of 100. 3 mg: Bottles of 100, cartons of 100 (blisters), cartons of 3.
Contraindications
Hypersensitivity to eszopiclone or zopiclone; myasthenia gravis; severe respiratory impairment (e.g., sleep apnea); elderly with potent CYP3A4 inhibitors or severe hepatic insufficiency.
Warnings and precautions
Risk of addiction, abuse, and misuse. Complex sleep-related behaviours (sleep-driving, etc.) can be fatal; discontinue immediately if they occur. Risk of next-day impairment.
What can be used instead?
Other Canadian products sharing ATC code N05CF04 ESZOPICLONE. 9 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LUNESTA | 1 MG | TABLET | SUMITOMO PHARMA CANADA, INC. | MARKETED | DIN 02453207 |
| LUNESTA | 2 MG | TABLET | SUMITOMO PHARMA CANADA, INC. | MARKETED | DIN 02453215 |
| LUNESTA | 3 MG | TABLET | SUMITOMO PHARMA CANADA, INC. | MARKETED | DIN 02453223 |
| M-ESZOPICLONE | 2 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02551195 |
| M-ESZOPICLONE | 3 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02551209 |
| MAR-ESZOPICLONE | 1 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02549433 |
| MAR-ESZOPICLONE | 2 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02549441 |
| MAR-ESZOPICLONE | 3 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02549468 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.